Please try another search
The 2023 Q3 earnings season kicks off tomorrow with major U.S. banks leading the way Despite the bleak backdrop, S&P 500's Q3 earnings outlook is not as bad as expected This earnings season is set...
Moderna (NASDAQ:MRNA) shares closed lower on Tuesday after the vaccine maker said that its vaccine against seasonal flu did not achieve “early success” in the Phase 3 trial. Following...
Biotech company Moderna (NASDAQ:MRNA) is seeing its shares trade under pressure in recent days after the company reported last week Phase 3 trial results for its flu vaccine candidate, mRNA-1010, in...
PCE inflation data, Fed FOMC minutes, retailer earnings in focus. Walmart stock is a buy amid strong results, upbeat guidance. Moderna shares set to underperform on big profit drop, sluggish...
MRNA is an exceptionally difficult stock to value, given enormous uncertainty surrounding its COVID-19 vaccine and other drugs in its pipeline But there is a case that an enterprise value still over...
The steep plunge in Moderna stock comes amid signs that the pandemic is moving towards an endemic stage The company still maintains a strong sales pipeline for its COVID vaccines, which should keep it...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review